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InﬂammationConstitutiveWnt/β-catenin signaling is a key contributor to colorectal cancer (CRC). Although inactivation of the
tumor suppressor adenomatous polyposis coli (APC) is recognized as an early event in CRC development, it is the
accumulation of multiple subsequent oncogenic insults facilitates malignant transformation. One potential con-
tributor to colorectal carcinogenesis is the POZ-ZF transcription factor Kaiso, whose depletion extends lifespan
and delays polyp onset in the widely used ApcMin/+ mouse model of intestinal cancer. These ﬁndings suggested
that Kaiso potentiates intestinal tumorigenesis, but this was paradoxical as Kaiso was previously implicated as
a negative regulator ofWnt/β-catenin signaling. To resolve Kaiso's role in intestinal tumorigenesis and canonical
Wnt signaling, we generated a transgenic mouse model (KaisoTg/+) expressing an intestinal-speciﬁc myc-tagged
Kaiso transgene. We then mated KaisoTg/+ and ApcMin/+ mice to generate KaisoTg/+:ApcMin/+ mice for further
characterization. KaisoTg/+:ApcMin/+mice exhibited reduced lifespan and increased polyp multiplicity compared
to ApcMin/+ mice. Consistent with this murine phenotype, we found increased Kaiso expression in human CRC
tissue, supporting a role for Kaiso in human CRC. Interestingly, Wnt target gene expression was increased in
KaisoTg/+:ApcMin/+ mice, suggesting that Kaiso's function as a negative regulator of canonical Wnt signaling, as
seen in Xenopus, is not maintained in this context. Notably, KaisoTg/+:ApcMin/+ mice exhibited increased inﬂam-
mation and activation of NFκB signaling compared to their ApcMin/+ counterparts. This phenotypewas consistent
with our previous report that KaisoTg/+mice exhibit chronic intestinal inﬂammation. Together our ﬁndings high-
light a role for Kaiso in promoting Wnt signaling, inﬂammation and tumorigenesis in the mammalian intestine.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
UncontrolledWnt signaling is a key contributor to CRC and identify-
ing proteins ormolecules thatmodulate this pathway have great poten-
tial for drug development for CRC treatment. In the past decade several
new Wnt/β-catenin regulators and pathways that negatively or posi-
tively modulate Wnt signaling have been discovered but a thorough
understanding of their roles in CRC remains unknown [1]. One novel
Wnt/β-catenin regulator is the POZ-ZF transcription factor Kaiso that
was ﬁrst identiﬁed as a binding partner for the Armadillo catenin and
cell adhesion cofactor p120ctn [2]. Kaiso is a unique dual-speciﬁcity
POZ-ZF transcription factor that binds DNA at methylated CpGtous polyposis coli; KBS, Kaiso
tory bowel disease
cMaster University, 1280 Maindinucleotides or a speciﬁc sequence known as the Kaiso Binding Site
(KBS) [2–4]. Although few bona ﬁde Kaiso target genes have been char-
acterized to date, evidence from Xenopus embryos andmammalian cul-
tured cells implicates Kaiso as a negative regulator of Wnt signaling,
possibly via its interaction with members of the Tcf family of transcrip-
tion factors and repression ofWnt target genes [5–8]. Surprisingly how-
ever, Kaiso depletion results in delayed polyp onset and prolonged
lifespan in the ApcMin/+ mouse model of intestinal neoplasia [9].
ApcMin/+ mice carry a nonsense mutation in codon 850 of the Apc
gene, which leads to a truncated and non-functional Apc polypeptide,
nuclear accumulation of β-catenin and constitutive activation of Wnt
target genes [10]. Given that Kaiso has been implicated as a negative
regulator of Wnt signaling, the unexpected delayed polyp onset in
Kaiso-null ApcMin/+ mice may be independent of Kaiso's function in
Wnt signaling. Indeed, Kaiso has been implicated in CRC progression via
non-Wnt mechanisms [11], but no study has speciﬁcally examined the
effects of Kaiso's overexpression on CRC development in mouse models.
Previously, we found that intestinal-speciﬁc KaisoTg/+ mice exhibit-
ed several phenotypic abnormalities including hyperplasia, villi fusion
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creased leukocyte inﬁltration of the lamina propria and neutrophil
activation, hinting that Kaiso may drive inﬂammation in the intestine
[12]. This idea is further supported by the ﬁnding thatmicewith limited
ablation of p120ctn (i.e. unregulated Kaiso function) in the intestine
developed chronic inﬂammation and adenomas [12]. Approximately
20% of all colorectal cancers can be attributed to genetic and familial
syndromes, while the remainder are due to sporadic mutations inﬂu-
enced by environmental factors [13,14]. Colitis-associated cancer
(CAC) is a CRC subtype that results from the occurrence of clinically de-
tectable, chronic intestinal inﬂammation in patients with inﬂammatory
bowel disease (IBD) [15–17]. IBD is characterized as the overactive im-
mune response to intestinal microbiota and other environmental stimuli
in genetically predisposed individuals, and increasing evidence indicates
that IBD increases the risk of CRC by up to 20% [18–20]. Our ﬁndings in
KaisoTg/+ mice, combined with previous studies implicating Kaiso in CRC
[9,11], led us to hypothesize that Kaiso may potentiate ApcMin/+ tumori-
genesis by predisposing the intestinal epithelium to inﬂammation in a
mechanism akin to CAC.
In this study, we mated our KaisoTg/+ mice with ApcMin/+ mice to
generate KaisoTg/+: ApcMin/+mice. Ectopic Kaiso expression signiﬁcantly
shortened the lifespan of ApcMin/+ mice and resulted in approximately
3-fold more polyps. KaisoTg/+:ApcMin/+ mice also presented with ex-
tensive regions of atypical hyperplasia, increased mitoses and focal
crypt abscesses, which were largely absent or present at a lower
frequency in age-matched ApcMin/+ mice. Examination of Wnt target
gene expression in KaisoTg/+ mice revealed that ectopic Kaiso expres-
sion increases the expression of Wnt target genes, and this effect is fur-
ther ampliﬁed in KaisoTg/+:ApcMin/+ mice. Lastly, KaisoTg/+:ApcMin/+
mice exhibited increased neutrophil activation and pro-inﬂammatory
cytokine production, possibly through the induction of NFκB signaling.
Together, our data suggest that Kaiso expression may induce intestinal
inﬂammation,which then predisposesmice to intestinal tumorigenesis.Table 1
qRT-PCR primer sequences and annealing temperatures.
Target Annealing temperature (°C) Primer sequences (5′–3′)
villin-mKaiso 55.0 Forward: caacttcctaagatctcccaggt
Reverse: caaggagttcagcagactgg
Gapdh 55.0 Forward: atgaccacagtccatgccatc
Reverse: cctgcttcaccaccttcttg
Axin2 57.0 Forward: tgtgagatccacggaaacag
Reverse: ctgcgatgcatctctctctg
Mmp7 57.0 Forward: gcggagatgctcactttgac
Reverse: gcatctatcacagcgtgttc
EphB2 65.2 Forward: ctgtggtcgtcattgccatc
Reverse: catgcctggggtcatgtgt
CD44 56.4 Forward: aacgagtgcaactacagcct
Reverse: ctccgtaccaggcatcttcg
Lect2 61.8 Forward: cgactgtctggaagaggtttttg
Reverse: ggtaaactttctgcaggggc2. Materials and methods
2.1. Mouse husbandry and mating
All mouse work was performed with the approval of the McMaster
Animal Research Ethics Board under Animal Utilization Protocol
#10-05-32. KaisoTg/+ mice were generated as previously described
[12]. Brieﬂy, Kaiso transgenic mice were generated by microinjection
of a myc-tagged villin-mKaiso transgene into 1-cell C57BL6/CBA hybrid
mouse embryos in vitro. villin-mKaiso-injected embryos were im-
planted into pseudopregnant foster mothers to produce transgenic
founder Lines A and E, which were backcrossed with C57BL/6N mice
(Taconic) for a minimum of 8 generations to obtain stable transgenic
offspring. KaisoTg/+ females were mated with ApcMin/+males (The Jack-
son Laboratory; C57BL6 background) to generate KaisoTg/+:ApcMin/+
mice. Axin2lacZ:KaisoTg/+ mice were generated by crossing Axin2lacZ fe-
males (The Jackson Laboratory; C57BL6 background) with KaisoTg/+
males. Pregnant females were fed a standard chow diet supplemented
with transgenic dough once a week. 21 day-old pups were transferred
to a Speciﬁc Pathogen Free (SPF) facility and fed a standard chow diet.
All mating was performed in a clean, vented-rack room at the McMaster
University Central Animal Facility (Hamilton ON). For KaisoTg/+:ApcMin/+
and ApcMin/+ mice, health monitoring was conducted daily and mice
wereweighed every 3 days until they exhibited signs of the experimental
endpoint, which was deﬁned as the point at which animals lost at least
15% of body weight and exhibited two or more of the following symp-
toms: poor body condition, profuse rectal bleeding, slow movement,
pale extremities. All animals were euthanized by CO2 asphyxiation,
followed by cervical dislocation. Measurements from both male and
female mice were included in all analyses, except for body weight mea-
surements where only male weights are depicted.2.2. Mouse tissue harvest
Following euthanasia, spleen, liver, small intestine and large intes-
tine tissueswere immediately harvested. Intestinal tissueswere ﬂushed
with cold 1× PBS, dissected longitudinally and either ﬂash frozen or
ﬁxed in phosphate-buffered formalin (PBF) for 48 h at room tempera-
ture (RT). Spleen and liver tissues were rinsed in cold 1× PBS and
ﬁxed in PBF for 48 h at RT. Intestinal tissues harvested for histological
and immunohistochemical (IHC) analyses were sectioned into 3 equal
sections and rolled into “Swiss rolls” before ﬁxation. Fixed tissues
were parafﬁn-embedded, sectioned into 5 μm slices and mounted
onto slides at the JohnMayberry Histology Facility at McMaster. Hema-
toxylin and eosin (H&E) stains were also performed by the John
Mayberry Histology Facility.
2.3. Polyp measurements
Fixed intestinal tissues were stained for 30 s in a 0.05% methylene
blue solution at RT. Tissues were washed repeatedly in 1× PBS until
polyps became easily distinguishable from surrounding intestinal
tissue. Polyps in stained intestinal sections were counted and polyp
area (mm2) was measured using ImageJ software. A Student's t-test
was performed to determine the statistical signiﬁcance of any differ-
ences observed.
2.4. Immunohistochemistry
IHC staining for Kaiso and Ki67 was performed as previously de-
scribed [12]. Staining for cleaved caspase-3 was performed using rabbit
anti-cleaved caspase-3 antibody (Asp 175) (Cell Signaling) at a 1:200
dilution. MMP-7 staining was performed using rat anti-MMP-7 anti-
body (Vanderbilt Antibody Resource) at a 1:200 dilution. NFκB staining
was performed using rabbit anti-NFκB antibody (Cell Signaling) at a
1:200 dilution. Colorectal cancer tissue microarrays (TMAs) were pur-
chased fromUSBiomax (Catalogue #: CO951 and BC05115) and stained
and scored for Kaiso expression. Immunostaining for cytoplasmic Kaiso
and nuclear Kaiso were evaluated separately. Immunostaining was
evaluated by determining the percentage of malignant cells in three
random ﬁelds on a scale of 0–4. Scores of 0 (no staining), 1 (10%), 2
(10–50%), 3 (50–75%), and 4 (75%) were assigned as previously de-
scribed [21,22]. F4/80 staining for macrophages was conducted by the
John Mayberry Histology Facility, McMaster University. All images
were acquired using the Aperio ScanScope and processed using
ImageScope software.
2.5. β-Galactosidase staining
Forβ-galactosidase staining, “Swiss-rolled” intestineswereﬂash fro-
zen in OCT (Tissue-Tek). Mounted tissues were ﬁxed in 0.2%
Fig. 1. Kaiso expression is increased in CRC patient biopsies and in KaisoTg/+:ApcMin/+
polyps. A) Comparison of Kaiso mRNA expression in human normal colon tissues, polyps,
primary tumors and metastases. B) IHC analysis and quantiﬁcation of Kaiso protein
expression in human primary colorectal tumors and metastases compared to normal colon
biopsies (**** represents p b 0.0001. Error bars indicate standard error of the mean).
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solution (0.02% NP-40, 0.01% sodium deoxycholate, 2 mM MgCl2) for
10 min at RT. Tissues were stained in a 1 mg/mL X-gal solution
(Sigma) for 24 h at 37 °C in the dark and washed 3 times in 1×
PBS for 2 min each. Post-ﬁxation was performed by incubating tis-
sues in 4% paraformaldehyde for 10 min. Tissues were counter-
stained with Nuclear Fast Red (Sigma) for 3 min at RT and rinsed
under running ddH2O for 5 min. Finally, tissues were dehydrated
in an ethanol series and cleared with xylenes.2.6. Myeloperoxidase (MPO) assay
50mgof ﬂash-frozen intestinal tissuewas homogenized in a volume
of HTAB buffer (0.5% hexadecyltrimethylammonium bromide in 50mM
phosphate buffer, pH 6.0) according to the formula VHTAB = mg of
tissue/50. Homogenates were cleared by centrifugation at 12,000 rpm
for 5 min at 4 °C. 200 μL of o-dianisidine dihydrochloride solution
(16.8 mg/mL o-dianisidine dihydrocholide in 5 mM phosphate buffer,
pH 6.0 with 50 μL of 1.2% H2O2) was mixed with 7 μL of tissue homoge-
nate and absorbance at 450 nm was measured 3 times at 30 secondFig. 2.Kaiso expression is increased inApcMin/+mice. A) Western blot demonstrating high
Kaiso expression in ApcMin/+ versus Non-Tg mice intestinal tissues. Intense nuclear stain-
ing for Kaiso was observed in ApcMin/+ polyps relative to adjacent villi and crypts where
Kaiso was localized to both the cytoplasm and the nucleus. Data is representative of at
least 3 independent trials performed with different mice. B) Kaiso expression in the
small intestines of KaisoTg/+:ApcMin/+ and ApcMin/+ mice.
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and the absorbances averaged to calculateMPOactivity.MPO activitywas
calculated in units (U),where 1U represents the amount ofMPO required
to degrade 1 μmol of H2O2/min at 25 °C, which gives an absorbance of
1.13 × 10−2 nm/min. MPO activity in each sample was determined as
the change in absorbance [ΔA(t2− t1) / Δmin]/(1.13 × 10−2).
2.7. Multiplex cytokine assay
Approximately 50 mg of fresh tissue was homogenized in buffer
containing 20 mM Tris HCl (pH 7.5), 0.5% Tween 20, 150 mM NaCl
and cOmplete Ultratablets (Roche) (1 tablet per 25 mL of buffer).
Tissue homogenates were diluted to contain equal amounts of total
protein (N400 μg/mL) and sent to Eve Technologies Corporation (Calgary,
Alberta) where cytokine content was measured in pg/mL using the
Mouse 32-Plex Cytokine Panel. A Student's t-testwas performed to deter-
mine the statistical signiﬁcance of any differences observed.
2.8. Western blot analysis
Western blot analysis was performed as described in [12]. Brieﬂy,
50 mg of intestinal tissue was homogenized in RIPA buffer and the
protein concentration of the resulting homogenates estimated using a
Bradford assay. 25–50 μg of denatured protein lysate was electropho-
resed on an SDS polyacrylamide gel, and then transferred to a nitrocel-
lulose membrane. Antibodies used were as follows: rabbit anti-Kaiso
polyclonal antibody at a 1:10,000dilution,mouse anti-β-actinmonoclo-
nal antibody (Sigma Aldrich) at a 1:30,000 dilution, rabbit anti-NFκBFig. 3. ApcMin/+ lifespan is attenuated by ectopic Kaiso expression. A) Kaplan–Meier survival cur
ApcMin/+ = 161.5 days vs. KaisoTg/+:ApcMin/+ Line A = 112.5 & Line E = 88.5 days; n ≥ 5, Log r
than their ApcMin/+ counterparts at 90 days of age. KaisoTg/+ Line A and Line E mice also weig
enhanced in KaisoTg/+:ApcMin/+ mice as indicated by loss of liver pigment (top panel) a
90 day-old KaisoTg/+:ApcMin/+ mice (n ≥ 18) (* represents p ≤ 0.05; ** represents p ≤ 0.01monoclonal antibody (Cell Signaling) at a 1:1000 dilution, rabbit anti-
pNFκB monoclonal antibody (Cell Signaling) at a 1:500 dilution, rabbit
anti-iNOS polyclonal antibody (Cell Signaling) at a 1:1000 dilution,
mouse anti-ICAM-1 monoclonal antibody (Santa Cruz Biotechnology)
at a 1:100 dilution, mouse anti-pIκBαmonoclonal antibody (Cell Signal-
ing) at a 1:500 dilution.
2.9. Gene expression analysis
Expression data from 123 primary colorectal cancer and 25 normal
patient biopsies were obtained from Gene Expression Omnibus (GEO
accession number GSE41258) [23]. Expression data were normalized
using robust-microarray analysis (RMA), quantile normalized and back-
ground corrected using RMA background correction. A Student's t-test
was performed to determine the signiﬁcance of any differences ob-
served between groups using GraphPad Prism 5 software.
2.10. Quantitative reverse-transcription PCR
Total RNAwas isolated from ﬂash-frozen tissues using the NucleoSpin
RNA kit (Macherey-Nagel) according to themanufacturer's protocol. 1 μg
of RNA from each sample was treated with DNase I (Invitrogen) and re-
verse transcribed using the qScript cDNA SuperMix (Quanta BioSciences)
according to the manufacturers' protocols. cDNAwas ampliﬁed using the
PerfeCta SYBR Green SuperMix, ROX (Quanta BioSciences). Each reaction
was performed in triplicate using the Applied BioSystems Prism 7900HT
sequence detection system. Primer sequences utilized for the targets
and their corresponding annealing temperatures are listed in Table 1.ve comparing survival of KaisoTg/+, ApcMin/+ and KaisoTg/+:ApcMin/+mice (median survival
ank test p b 0.0001). B) KaisoTg/+:ApcMin/+ Line A and Line E mice weigh signiﬁcantly less
h less than their Non-Tg littermates at this age (n ≥ 5). C) Anemia and splenomegaly are
nd enlarged spleen (bottom panel). D) Spleen weight is signiﬁcantly increased in
; **** represents p b 0.0001. Error bars indicate standard error of the mean).
Fig. 4. Ectopic Kaiso enhances polyp formation in ApcMin/+ mice. A) KaisoTg/+:ApcMin/+
mice exhibit extensive regions of focal atypical hyperplasia (i, ii, red arrowheads) and
formed adenomas (i, white arrowhead) compared to their ApcMin/+ counterparts (ii),
which exhibit mostly focal early adenomas (black arrowheads). Representative images
from pathological examination of 3 mice/genotype. B) KaisoTg/+:ApcMin/+ mice exhibit
signiﬁcantly more polyps than ApcMin/+ mice (n ≥ 6) (** represents p ≤ 0.01; **** repre-
sents p b 0.0001. Error bars indicate standard error of the mean).
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was normalized to Gapdh expression levels. The standard curve was con-
structed using 5-fold serial dilutions of cDNA reverse transcribed from a
mixture of RNA from all mice. Statistical analyses were conducted using
GraphPad Prism software. Statistical signiﬁcance was calculated using a
Student's t-test with measurements from at least 4 independent trials.
3. Results
3.1. Kaiso expression is increased in human colorectal tumor tissues and
ApcMin/+ polyps
Previous studies have implicated Kaiso in intestinal tumorigenesis
utilizing murine models and cultured colorectal cancer cell lines [9,
11]. However, no study has examined the expression of Kaiso in a
large cohort of CRC patient tissues.We analyzed KaisomRNAexpression
in a gene expression data set from human colon biopsies, consisting of
74 normal colon tissues, 49 colonic polyp tissues, 186 primary colorectal
tumor tissues and 69metastases [23]. Kaiso expressionwas signiﬁcantly
increased in polyps and primary tumors compared to normal tissues
(p b 0.0001 and p b 0.0001, respectively) (Fig. 1A). KaisomRNA expres-
sion was also increased in metastases, although this increase was not
signiﬁcant (Fig. 1A). To complement our bioinformatics studies, we
examined Kaiso protein expression in two CRC tissue microarrays that
consisted of 17 normal colon tissues, 60 primary tumor tissues and 40
metastases (US Biomax, MD, USA). In agreement with our bioinformatics
analysis, Kaiso expressionwas largely absent or low in normal colon biop-
sies compared to primary and metastatic tumor biopsies (p b 0.0001 and
p b 0.0001, respectively) where robust Kaiso staining was observed
(Fig. 1B). While our analysis of Kaiso expression does not demonstrate a
causal relationship between Kaiso and CRC progression, the analysis
supports the idea that high Kaiso expression correlates with increasing
malignancy.
We next examined Kaiso expression in ApcMin/+ mice compared
to non-transgenic (Non-Tg) mice. Since ApcMin/+ mice develop polyps
primarily in the small intestine [24], we focused our studies on the
small intestine unless otherwise stated. Nuclear Kaiso expression was
increased in polyps relative to the surrounding intestinal epithelium
(Fig. 2A & B) and relative to that of Non-Tg mice (data not shown).
Immunoblot analysis also conﬁrmed increased expression of Kaiso in
ApcMin/+ intestinal homogenates compared to Non-Tg mice (Fig. 2A).
3.2. Kaiso overexpression signiﬁcantly attenuates the lifespan of
ApcMin/+ mice
Previous studies investigating the effect of Kaiso depletion on
murine development demonstrated that Kaiso-null mice exhibited no
deleterious developmental defects [9]. Interestingly however, when
Kaiso-null mice were mated with ApcMin/+ mice the resultant progeny
exhibited prolonged lifespan and decreased polyp size, although no
change in polyp number was observed [9].
To conﬁrm and extend the studies of Prokhortchouk et al., we gener-
ated and characterized amousemodel expressing an intestinal-speciﬁc,
murine myc-tagged Kaiso transgene [12]. We opted for a transgenic
approach to overcome the potential effects of functional redundancy
between Kaiso and the Kaiso-like proteins ZBTB4 and ZBTB38 that
may have precluded effective resolution of Kaiso's role in the Kaiso
knockoutmodel. Up to 12months of age,KaisoTg/+mice did not develop
polyps, but they displayed crypt hyperplasia and dysplasia of varying
severities [12]. To facilitate our investigation of Kaiso's role in intestinal
tumorigenesis, we utilized the ApcMin/+model of colon cancer as a sen-
sitized background andmated thesemicewith two independently gen-
erated KaisoTg/+ lines to generateKaisoTg/+:ApcMin/+mice. KaisoTg/+ Line
Emice expressmore ectopic Kaiso than KaisoTg/+ Line Amice, indicative
of a higher transgene copy number [12]. As expected, KaisoTg/+:ApcMin/+
mice exhibited robust nuclear Kaiso staining in both the polyps and theintestinal epithelium (Fig. 2B). However, Kaiso expression in KaisoTg/+:
ApcMin/+ polyps was heterogeneous, with some cells expressing more
Kaiso than others (Fig. 2B). Additionally, although Kaiso expression
was increased in the crypts of KaisoTg/+:ApcMin/+ mice compared to
ApcMin/+ mice, crypt staining was not as pronounced as that observed
in the villi, where both nuclear and cytoplasmic Kaiso was evident.
We recently reported that KaisoTg/+ mice exhibited normal lifespan
and that no intestinal polyps were detected in KaisoTg/+ Line A mice
up to one year of age although the mice exhibited crypt hyperplasia
[12]. However, KaisoTg/+:ApcMin/+ mice exhibited signiﬁcantly reduced
lifespan compared to ApcMin/+ mice (p b 0.0001) in a dose-dependent
manner, i.e. KaisoTg/+:ApcMin/+ Line E mice (high Kaiso expression) ex-
hibited signiﬁcantly reduced lifespan compared to KaisoTg/+:ApcMin/+
Line A mice (moderate Kaiso expression) (p b 0.05), suggesting that in-
creased transgene dosage results in a more severe phenotype (Fig. 3A).
Overall health, as indicated by weight and liver pigment, were also
assessed in age-matched 90 day-old KaisoTg/+:ApcMin/+ and ApcMin/+
mice since loss of 15% of body mass and anemia are often used as end-
point indicators in ApcMin/+ mice. At 90 days of age, both KaisoTg/+:
ApcMin/+ Line A and Line E mice weighed less than their ApcMin/+
counterparts (Fig. 3B). No signiﬁcant difference in weight between
KaisoTg/+:ApcMin/+ Line A and Line E mice was observed, although
the signiﬁcantly diminished lifespan of KaisoTg/+:ApcMin/+ Line E
mice precluded weight measurement of a larger sample size. Notably,
KaisoTg/+ Line E mice also weighed signiﬁcantly less than their Non-Tg
counterparts (Fig. 3B), suggesting that ectopic Kaiso expression results
in decreased weight even in the absence of the Min mutation. At
90 days of age,KaisoTg/+:ApcMin/+mice exhibited decreased liver pigment,
whileApcMin/+mice livers showed little to no loss of pigment (Fig. 3C, Top
Panel). We also noted that KaisoTg/+:ApcMin/+ mice had grossly enlarged
spleens, which weighed signiﬁcantly more than spleens isolated from
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if any, of these enlarged spleens to the KaisoTg/+:ApcMin/+mice phenotype
or CRC is unknown.
3.3. Polyp burden is increased in KaisoTg/+:ApcMin/+ mice
We next examined the polyp burden of KaisoTg/+:ApcMin/+ mice.
Gross histological examination of the small intestines from KaisoTg/+:
ApcMin/+ mice revealed extensive regions of focal atypical hyperplasia
(Fig. 4A-i) and increased mitoses. Regions of atypical hyperplasia were
also evident in ApcMin/+ mice, albeit at a much lower frequency
(Fig. 4A-ii). KaisoTg/+:ApcMin/+ mice also exhibited increased numbers
of early adenomas and numerous formed adenomas, which were largely
absent in ApcMin/+ mice (Figs. 4A-i & ii). More importantly, KaisoTg/+:
ApcMin/+ Line A mice exhibited ~2.5-fold more and Line E mice ~5-fold
more polyps at death than ApcMin/+ mice. At 90 days of age, KaisoTg/+:
ApcMin/+ Line A mice exhibited ~3-fold more polyps than age-matched
ApcMin/+ mice, suggesting that increased Kaiso expression accelerates
polyp onset (Fig. 4B).
KaisoTg/+:ApcMin/+ polyps were signiﬁcantly smaller than those of
ApcMin/+mice at both 90 days of age and at death (~110 days), although
this difference was more apparent at death (Fig. 5A-i). We postulated
that the decreased polyp size in KaisoTg/+:ApcMin/+ mice may be at-
tributed to the signiﬁcantly shortened lifespan of these mice compared
to their ApcMin/+ counterparts. Indeed, the size distribution of polyps in
KaisoTg/+:ApcMin/+mice at 90 days of age was similar to that of ApcMin/+Fig. 5. KaisoTg/+:ApcMin/+ mice have smaller polyps than ApcMin/+ mice at death. A) Intestinal p
ApcMin/+ mice (n ≥ 292) (left panel). Age-matched ApcMin/+ and KaisoTg/+:ApcMin/+ mice exhib
fewer polyps greater than 3 mm2 at death (right panel). B) Staining for the proliferation ma
mice. C) Percentage of apoptotic cells per polyp is greater in KaisoTg/+:ApcMin/+ mice. Images d
(* represents p ≤ 0.05; ** represents p ≤ 0.01; **** represents p b 0.0001. Error bars indicate stamice (Fig. 5A-ii). However, at death, KaisoTg/+:ApcMin/+ mice exhib-
ited fewer polyps of 3 mm2 or larger, but a greater proportion of
polyps less than 1 mm2 and 1–3 mm2 compared to their ApcMin/+
counterparts (Fig. 5A-iii).
Although the reduced polyp size in KaisoTg/+:ApcMin/+mice could be
attributed to their shortened lifespan, it remained possible that the
reduced polyp size could also be attributed to decreased proliferation
or increased apoptosis. Staining for the proliferation marker Ki67 re-
vealed no difference in proliferation between Non-Tg and KaisoTg/+
mice or between ApcMin/+ and KaisoTg/+:ApcMin/+ mice at 90 days of
age (Fig. 5B). To measure apoptosis, intestinal sections were stained
for cleaved caspase-3 [25] and the percentage of apoptotic cells/polyp
determined. KaisoTg/+:ApcMin/+ mice exhibited more cleaved caspase-
3-positive cells than ApcMin/+ mice, suggesting that ectopic Kaiso ex-
pression increases apoptosis in intestinal polyps, which may contribute
to the decreased polyp size seen in KaisoTg/+:ApcMin/+ mice (Fig. 5C).
3.4. Wnt signaling is upregulated upon ectopic expression of Kaiso
Our ﬁnding that ectopic Kaiso expression increases polyp burden
while Kaiso loss delays polyp onset in the ApcMin/+ mouse model [9] is
paradoxical in light of previous studieswhere Kaiso has been implicated
as a negative regulator of canonicalWnt signaling [6,26]. Ourﬁndings in
the KaisoTg/+:ApcMin/+model thus raised the possibility that Kaiso's role
as a negative regulator of Wnt signaling may be context dependent. To
clarify Kaiso's function in regulating Wnt signaling in the intestine weolyps of Line A and Line E KaisoTg/+:ApcMin/+ mice are signiﬁcantly smaller than those of
it no difference in size distribution of polyps at 90 days of age (middle panel) but exhibit
rker Ki67 revealed no change in proliferation between ApcMin/+ and KaisoTg/+:ApcMin/+
epicted for Ki67 and cleaved-caspase 3 staining are representative of 3 independent trials
ndard error of the mean).
1852 C.C. Pierre et al. / Biochimica et Biophysica Acta 1852 (2015) 1846–1855examined the effect of ectopic Kaiso expression onWnt target gene ex-
pression. KaisoTg/+micewere crossedwith heterozygous Axin2lacZmice,
a Wnt reporter line in which the DNA sequence encoding a nuclear-
localized β-galactosidase (NLS-lacZ) is inserted in-frame into exon
2 of the endogenous Wnt target gene Axin2 [27]. Surprisingly,
Axin2lacZ:KaisoTg/+ mice exhibited increased expression of β-
galactosidase compared to Axin2lacZ mice (Fig. 6A). Consistent
with this ﬁnding, KaisoTg/+ mice and KaisoTg/+:ApcMin/+ mice ex-
hibited increased expression of another Wnt target gene, MMP-7,
compared to control mice (Fig. 6B). To conﬁrm that Kaiso was pos-
itively regulating Wnt/β-catenin target gene expression in murine
intestines, we examined the mRNA expression of four established
Wnt target genes (MMP7, Axin2, CD44 and EphB2) in the intestine
using qRT-PCR. The expression of all four target genes was signiﬁ-
cantly increased in KaisoTg/+:ApcMin/+ mice relative to control
mice, (p b 0.05) (Fig. 6C). Interestingly, KaisoTg/+ mice also exhibit-
ed increased expression of all four target genes, although these
changes were not signiﬁcant (Fig. 6C). Expression of β-catenin
remained relatively unchanged across all 4 genotypes (data not
shown), but expression of the Wnt pathway antagonist Lect2 was
signiﬁcantly decreased in KaisoTg/+ mice relative to Non-Tg mice
(Fig. 6D). Collectively, these data suggest that Kaiso's transcrip-
tional repression effects on Wnt signaling are context-dependent
and are not maintained in the ApcMin/+ model.Fig. 6. Kaiso potentiates Wnt signaling in the intestine: A) Axin2lacZ:KaisoTg/+ mice
exhibit increased Wnt reporter activity. B) MMP7 expression is increased in KaisoTg/+ and
KaisoTg/+:ApcMin/+mice relative to their respective controls. Images depictingβ-galactosidase
and MMP-7 staining are representative of at least 3 independent trials. C) mRNA expression
of Wnt target genes in KaisoTg/+, KaisoTg/+:ApcMin/+ and control mice (n ≤ 5).
D) Expression of theWnt antagonist Lect2 is reduced inKaisoTg/+mice (n ≤ 5) (* represents
p ≤ 0.05; *** represents p ≤ 0.001; **** represents p b 0.0001. Error bars indicate standard
error of the mean).3.5. Kaiso induces inﬂammation in ApcMin/+ mice
Previously, we found that 12 month-old KaisoTg/+ mice exhibited
signs of chronic intestinal inﬂammation, i.e. villi blunting, leukocyte in-
ﬁltration and neutrophil activation [12] but it was unclear whether the
Kaiso-induced inﬂammation occurred at younger ages.Whenwe exam-
ined the ileum of 90 day-old Line A KaisoTg/+ mice (when intestinal
polyps are alreadywell-developed in KaisoTg/+:ApcMin/+mice), an intes-
tinal inﬂammation phenotype was evident albeit at a lower frequency
than that observed in older mice (Fig. 7A). Extensive macrophage re-
cruitment was also evident in inﬂamed epithelia overlying Peyer's
patches in the ileum of Line A KaisoTg/+ mice as measured by F4/
80 staining (Fig. 7B). We also noticed several crypt abscesses in
our KaisoTg/+:ApcMin/+mice (Fig. 7C), reminiscent of those frequently ob-
served in the colon of patients with IBD. However, abscesses were
completely absent in both Line A KaisoTg/+ and ApcMin/+ mice (data not
shown).
We next performed an MPO assay on intestinal homogenates to as-
sess neutrophil activation as a surrogate marker for inﬂammation. No
signiﬁcant change in MPO activity was observed in 90 day-old KaisoTg/+
mice relative to Non-Tg mice (data not shown), but a 6-fold increase in
activity was observed in both the small and large intestines of 90 day-
old KaisoTg/+:ApcMin/+ mice relative to ApcMin/+ mice (Fig. 7D). Several
pro-inﬂammatory cytokines and chemokines associated with innate im-
munity were also enriched in KaisoTg/+:ApcMin/+ intestinal homogenates,
namely granulocyte stimulating factors GM-CSF and G-CSF, eotaxin, IL-
3, IL-7, LIF, MCP-1 and MIP1B (Fig. 7E).
Since the Kaiso binding partner p120ctn has been implicated as
an anti-inﬂammatory mediator in multiple tissues and was postu-
lated to act through the NFκB signaling pathway, we examined
NFκB expression in KaisoTg/+:ApcMin/+ intestinal tissues. We detect-
ed increased nuclear NFκB in intestinal epithelial cells of KaisoTg/+
and KaisoTg/+:ApcMin/+ mice (Fig. 7F). Immunoblot analysis further
revealed activation of the NFκB pathway as evidenced by increased
expression of iNOS, ICAM-1 and phospho-NFκB (Fig. 7G). Notably
we also detected a modest decrease in expression of the NFκB inhib-
itor IκB-α (Fig. 7G). Collectively these data suggest that the in-
creased polyp burden in KaisoTg/+:ApcMin/+ mice may in part be
due to Kaiso-induced intestinal inﬂammation that involves activa-
tion of the NFκB pathway.
1853C.C. Pierre et al. / Biochimica et Biophysica Acta 1852 (2015) 1846–18554. Discussion
Kaiso has been implicated in the development and progression of
several human cancers, including colorectal cancer [5,9,11,22,28–34].
To date however, most studies examining Kaiso's role in cancer have
been largely correlative [9,29–31,33], while those offering mechanistic
insight have been performed primarily in mammalian cultured cells
[11,22,28,32,34]. Herewe describe the ﬁrst study to examine a potential
mechanistic role of Kaiso in colorectal cancer using the ApcMin/+ mouse
model of intestinal cancer.Fig. 7. KaisoTg/+:ApcMin/+ mice exhibit intestinal inﬂammation. A) H&E image showing villi blu
lamina propria (red dotted line) in 90 day-old KaisoTg/+mice, phenotypes that are absent in age-m
cruitment of these immune cells to an inﬂamed region in the ileum of 90 day-old KaisoTg/+ throu
images representative of 3 independent trials. D) MPO activity is increased in small and
cytokines are upregulated in KaisoTg/+:ApcMin/+ mice (n ≤ 10). F) NFκB localizes to the nucleus in
tissues relative to ApcMin/+ controls as evidenced by increased expression of iNOS and ICAM-
p ≤ 0.01; *** represents p ≤ 0.001; **** represents p b 0.0001. Error bars indicate standard error ofAs previously reported, Kaiso depletion extends the lifespan of
ApcMin/+ mice [9], and therefore our ﬁnding that ectopic Kaiso ex-
pression decreases the lifespan of ApcMin/+ mice was not surprising.
However, unlike the Prokhortchouk et al. study, which reported no
difference in the number of polyps between Kaiso-null ApcMin/+
and ApcMin/+ mice [9], we found increased polyp numbers in
KaisoTg/+:ApcMin/+ compared to ApcMin/+ mice. Notwithstanding
the disadvantages associated with the use of transgenic mouse models,
our study highlights one advantage of the KaisoTg/+ model; namely
that certain effects arising from Kaiso depletion models may be maskednting (black arrowhead), villi fusion (red arrow head) and immune cell inﬁltration of the
atched Non-Tg mice. B) F4/80 staining for macrophages and activated monocytes shows re-
gh a Peyer's patch. C) H&E image of crypt abscesses observed in KaisoTg/+:ApcMin/+ mice. All
large intestines (SI & LI) of KaisoTg/+:ApcMin/+ mice (n ≤ 11). E) Pro-inﬂammatory
KaisoTg/+ and KaisoTg/+:ApcMin/+tissues. G) NFκB signaling is activated in KaisoTg/+:ApcMin/+
1. All images representative of 3 independent trials (* represents p ≤ 0.05; ** represents
the mean).
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other methyl-DNA-binding proteins that may function redundantly
with Kaiso [35]. Indeed, this may explain why KaisoTg/+:ApcMin/+ mice
exhibited more polyps than ApcMin/+ mice, while Kaiso-null ApcMin/+
mice did not exhibit the opposite effect (i.e. less polyps) [9].
The ﬁnding that ectopic Kaiso expression increases polyp number
but decreases polyp size was surprising, since typically polyp number
and size are positively correlated. KaisoTg/+:ApcMin/+mice exhibit histo-
logically more advanced tumors than age-matched ApcMin/+ mice, al-
though there was no difference in tumor proliferation rate, suggesting
that KaisoTg/+:ApcMin/+ mice tumors form earlier. Although the signiﬁ-
cantly shortened lifespan of KaisoTg/+:ApcMin/+ mice may account for
the smaller tumor size, we also observed a larger number of cleaved-
caspase 3 positive cells in the polyps of KaisoTg/+:ApcMin/+ mice. Previ-
ous studies have demonstrated roles for Kaiso in cell cycle arrest and ap-
optosis [36,37]. Kaiso knockout mice exhibited increased expression of
Bcl6, which in turn increased the expression of the cell cycle regulatory
genes, p27 (Cdkn1b), p21 (Cdkn1a) and Gadd45a [37]. Kaiso has also
been shown to couple with p53 to promote the expression of p21 and
the pro-apoptotic genes BAX and PUMA, and consequently, Kaiso deple-
tion protects against etoposide-induced apoptosis in MEF cells [36].
These studies coupled with our observation of increased apoptotic
cells in KaisoTg/+:ApcMin/+ polyps, supports the idea that the smaller
polyps observed in KaisoTg/+:ApcMin/+ mice may be due, at least in part,
to a Kaiso-induced increase in apoptosis.
Consistent with our previous ﬁndings that KaisoTg/+ mice exhib-
ited intestinal inﬂammation, KaisoTg/+:ApcMin/+ mice likewise ex-
hibited enhanced intestinal inﬂammation. The onset of inﬂammation
seems to be accelerated in the presence of the Min allele, consistent
with reports that polyp formation is accompaniedby increased inﬂamma-
tion in ApcMin/+ mice [38]. Our initial investigation of the mechanism by
which Kaiso promotes inﬂammation suggests that Kaiso's role in inﬂam-
mationmay be linked to its binding partner p120ctn that has been charac-
terized as an anti-inﬂammatorymediator in several tissues, including the
intestine [39–43]. Conditional p120ctn depletion inmurine intestines trig-
ger acute inﬂammation and lethality at less than21days of age [39],while
limited p120ctn ablation (~15% of the intestinal epithelium) results in
chronic inﬂammation and adenoma formation [40].While the cause of in-
ﬂammation following p120ctn depletion in the intestine is not fully under-
stood, signiﬁcant barrier defects due to decreased E-cadherin expression
may be a contributing factor [40]. Remarkably, KaisoTg/+mice also exhibit
a barrier defect, but there was no apparent decrease in p120ctn or
E-cadherin expression, suggesting that the barrier defect in KaisoTg/+
micemay be a consequence rather than a cause of inﬂammation (our un-
published data). However recent studies suggest that p120ctn pro-
inﬂammatory effects may also be mediated through the NFκB pathway
[40–44] and indeed, we found that NFκB pathway signaling is increased
inKaisoTg/+ andKaisoTg/+;ApcMin/+mice. Ongoing studies are thus focused
on characterizing the interplay between Kaiso and p120ctn in regulating
inﬂammation in the intestine.
One major goal of this study was to clarify whether Kaiso's pos-
tulated function as a negative regulator of the Wnt signaling path-
way is maintained in the murine intestine. We found that contrary
to ﬁndings in Xenopus embryos and mammalian cultured cells [6,8,
26], ectopic Kaiso expression increased Wnt target gene expression.
While this was initially surprising and unexpected, such an outcome
could be explained by the fact that Kaiso has both transcriptional repres-
sion and activation roles [45,46]. Alternately, the active Wnt signaling in
mammalian intestines may be promoting p120ctn's interaction with
Kaiso and relieving Kaiso's inhibition of β-catenin/TCF transcriptional ac-
tivation, as recently observed by del Valle-Perez et al. [8]. Such a possibil-
ity is also consistent with the Xenopusmodels proposed by Ruzov et al.
[26], who suggest that the interaction between Kaiso and Tcf results in
their mutual disengagement fromWnt target genes. Since Wnt signaling
is most active in the intestinal crypts where it regulates the proliferation
and differentiation of intestinal stem cells [47], it is conceivable that theactive Wnt signaling in intestinal crypts promotes Kaiso's dissociation
from Tcf4, thereby inhibiting Kaiso's repressive effects on Wnt target
genes. However, since the majority of polyps in ApcMin/+ mice have un-
dergone a loss of heterozygosity at the Apc locus [13], the increased
Wnt target gene expression observed in KaisoTg/+:ApcMin/+ mice may be
also partially attributed to the signiﬁcantly higher polyp burden.
An additional explanation for Kaiso's potentiation of Wnt signaling
in the murine intestine may involve Kaiso's role in epigenetic or
methylation-dependent gene silencing [48,49]. Multiple Wnt antago-
nists are downregulated through promoter hypermethylation in colo-
rectal cancer [50–53]. For instance, MBD2 binds and regulates the
modestly characterized Wnt pathway repressor Lect2,which functions
to repress Wnt target gene expression at or below the level of TCF
[53]. Our detection of decreased Lect2 mRNA expression in KaisoTg/+
mice suggests that Kaiso's stimulatory effect on Wnt signaling may be
attributed to Kaiso-mediated methylation-dependent silencing of Wnt
pathway antagonists.
In conclusion, the correlation between increased Kaiso expres-
sion and neoplastic progression in human colorectal cancer tissues,
coupled with our ﬁndings that Kaiso overexpression potentiates
Wnt-mediated polyp formation, Wnt target gene expression and in-
ﬂammation in ApcMin/+mice, suggest that Kaiso may function in several
distinct oncogenic capacities in colorectal cancer pathogenesis.
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